TY - CHAP M1 - Book, Section TI - Adoptive T Cell Therapy for Haematological Malignancies A1 - Benjamin, Reuben A1 - Graham, Charlotte A2 - Board, Ruth E. A2 - Nathan, Paul A2 - Newsom-Davis, Tom A2 - Papa, Sophie A2 - Johnson, Peter Y1 - 2019 N1 - T2 - Problem Solving in Cancer Immunotherapy AB - The anticancer potential of the immune system has long been recognized in haematological malignancies, with allogeneic stem cell transplantation and donor lymphocyte infusions now established as standards of care for acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL) and some types of lymphomas. In addition, immunomodulatory drugs and monoclonal antibodies that trigger antibody-dependent cell-mediated cytotoxicity have been shown to be effective treatments for multiple myeloma and B cell lymphomas (e.g. B cell non-Hodgkin lymphoma [B-NHL]). The accessibility of bone marrow and lymph nodes (the predominant sites of haematological tumours) to circulating immune cells, as well as their susceptibility to immune cell-mediated killing, makes them an obvious target for adoptive T cell therapy (ACT). It was, however, the discovery that T lymphocytes could be retargeted to tumour cells, independently of the major histocompatibility complex (MHC), using chimeric antigen receptors (CARs) that fuelled interest in the field of ACT for haematological malignancies. SN - PB - EBN Health CY - New York, NY Y2 - 2021/03/05 UR - hemonc.mhmedical.com/content.aspx?aid=1160632881 ER -